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A growing body of evidence has indicated that energymetabolism impairmentmay be involved in patho-
physiology of some neuropsychiatric disorders. In this study, we evaluated the effect of acute and chronic
administration of ﬂuoxetine, olanzapine and the combination of ﬂuoxetine/olanzapine on citrate syn-
thase activity in brain of rats. For acute treatment, Wistar rats received one single injection of olanzapine
(3 or 6mg/kg) and/or ﬂuoxetine (12.5 or 25mg/kg). For chronic treatment, rats received daily injections
of olanzapine (3 or 6mg/kg) and/or ﬂuoxetine (12.5 or 25mg/kg) for 28 days. In the present study welanzapine
luoxetine
ood disorders
observed that acute administration of olanzapine inhibited citrate synthase activity in cerebellum and
prefrontal cortex. The acute administration of olanzapine increased citrate synthase activity in prefrontal
cortex, hippocampus and striatum and ﬂuoxetine increased citrate synthase activity in striatum. Olanza-
pine 3mg/kg and ﬂuoxetine 12.5mg/kg in combination increased citrate synthase activity in prefrontal
cortex, hippocampus and striatum. In the chronic treatment we did not observed any effect on citrate
synthase activity. Our results showed that olanzapine and ﬂuoxetine increased citrate synthase activity
ic treafter acute, but not chron
ntroduction
Mood disorders are among the most prevalent forms of mental
llness. Severe forms of depression affect 2–5% of the U.S. pop-
lation, and up to 20% suffer from milder forms of the illness.
nother roughly 1–2% are afﬂicted by bipolar disorder (also known
smanic-depressive illness) or its less severevariants [32] andwere
ssociated with higher rates of suicide and work loss [2,18,40].
Among persons with major depression, 75–85% have recurrent
pisodes [28]; 10–30% recover incompletely and have persistent,
esidual depressive symptoms [21]. Several combinations of effec-
ive treatments have been used in the search for higher response
ates or more rapid responses than monotherapy to diminish
reatment-resistant depression [7,26,36]. One strategy is to com-
ineof theantipsychoticdrugolanzapineplusantidepressantdrugs
31]. Accordingly, olanzapine plus ﬂuoxetine is an approved ther-
py for treating humandepression [6]. In preclinical studies inmale
ats, olanzapine [8] or ﬂuoxetine [41], alone or combined [24], pro-
uce antidepressant-like effects. In addition, a ﬁxed combination of
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olanzapine and ﬂuoxetine has been introduced for the treatment
of bipolar depression [2].
Evidence from the literature strongly indicates that metabolism
impairment may be involved in pathophysiology of some neu-
ropsychiatric disorders, such as bipolar disorder and major
depression [5,16,17,20,33,38,42]. In fact, our group recently
demonstrated that rats submitted to the chronic mild stress
increased oxidative stress in submitochondrial particles into the
brain [20]. In addition studies reported that rats submitted to the
animalmodel ofmaniawere reduced the creatinekinase andcitrate
synthase activity inbrain [5,38], suggesting that creatinekinase and
citrate synthase are involved in mood disorder. Very recently, we
also demonstrated that acute and chronic treatments with olanza-
pine and ﬂuoxetine (alone or in combination) alter creatine kinase
activity in rat brain [1]. In addition, abnormalities in respiratory
complexes activity and energy production may lead to cellular
degeneration [4].
Citrate synthase (EC 4.1.3.7) is localizedwithin cells in themito-
Open access under the Elsevier OA license.chondrial matrix and catalyzes the condensation of oxaloacetate
and the acetyl group of acetyl coenzyme-A (acetyl CoA), the ﬁrst
step of Krebs cycle. In this step, oxaloacetate reacts with acetyl
CoA and H2O to yield citrate and CoA. This enzyme is inhibited by
high amounts of ATP, acetyl CoA and NADH, when the cell energy
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upplied is high. This regulation ensures that Krebs cycle will not
xidise an excess of pyruvate and acetyl CoA when ATP concentra-
ions in cell arehigh [37]. In addition, citrate synthasehasbeenused
s a quantitative enzyme marker for the presence of intact mito-
hondria [23]. Therefore, considering that citrate synthase plays an
mportant role in brain energy metabolism and that mitochondrial
ysfunction is probably involved in the pathophysiology of bipo-
ar disorder and major depression, the objective of this study was
o investigate the effects of olanzapine and ﬂuoxetine (alone or in
ombination) on citrate synthase activity in rat brain.
xperimental procedure
nimals
Male adult Wistar rats (60 days old) were obtained from UNESC
Universidade do Extremo Sul Catarinense, Criciúma, SC, Brazil)
reeding colony. They were housed ﬁve per cage with food and
ater availablead libitum andweremaintainedona12-h light/dark
ycle (lights on at 7:00 AM). All experimental procedures involving
nimals were performed in accordance with the NIH Guide for the
are and Use of Laboratory Animals and the Brazilian Society for
euroscience and Behavior (SBNeC) recommendations for animal
are and with approval by local Ethics Committee under protocol
umber 510/2006.
rugs and treatments
Olanzapine (ZyprexaTM) and ﬂuoxetine (ProzacTM) were pro-
ided from Eli Lilly do Brasil Ltda, São Paulo, Brazil. Animals
eceived daily intraperitoneal injections of olanzapine (3 or
mg/kg), ﬂuoxetine (12.5 or 25mg/kg) or combination of both
rugs for 28 days in two protocols of chronic model, and in the
cute model for one day. The doses and protocols were executed
ollowing study described byAgostinho et al. [1]. All the drugswere
issolved in Tween 1% solution (vehicle). Control animals received
ehicle (1.0mL/kg). In the acute protocol, after the single injection,
he animalswere killed 2h after by decapitation, and the prefrontal
ortex, hippocampus and striatum were immediately removed.
imilarly, in the chronic protocols, the animals were killed 2 and
4h after the last injection, and the same areas are removed [1].
fter that, the activity of citrate synthase was measured.
itrate synthase activity
Prefrontal cortex, hippocampus and striatum were homoge-
ized (1:10, w/v) in SETH buffer (0.25M sucrose, 1mM EDTA,
0mM Tris–HCl, pH 7.4). The homogenates were centrifuged at
00× g for 10min and the supernatants were kept at −80 ◦C until
t will be used for enzyme activity determination. Protein content
as determined by the method described by Lowry et al. [19] using
ovine serum albumin as standard. Citrate synthase activity was
ssayed according to the method described by Shepherd and Gar-
and [37]. The reaction mixture contained 100mM Tris, pH 8.0,
00mM acetyl CoA, 100mM 5,5′-di-thiobis-(2-nitrobenzoic acid),
.1% triton X-100, and 2–4g supernatant protein and was initi-
ted with 100M oxaloacetate and monitored at 412nm for 3min
t 25 ◦C (the ﬁnal volume of reaction mixture was 0.3mL).
tatistical analysisData were analyzed by one-way analysis of variance (ANOVA)
ollowed by Tukey’s test when F was signiﬁcant and presented
s mean± S.E.M. All analysis were performed using the Statistical
ackage for the Social Science (SPSS) software version 16.0.Letters 487 (2011) 278–281 279
Results
As depicted in Fig. 1(A), the acute administration of olanza-
pine in dose of 6mg/kg and olanzapine 3mg/kg in combination
with ﬂuoxetine 25mg/kg increased citrate synthase activity in pre-
frontal cortex of rats (ANOVA, F(8–27) = 18.08; p<0.05; Fig. 1(A)).
Acute administration of olanzapine in dose of 3mg/kg alone and in
combination with ﬂuoxetine 25mg/kg increased citrate synthase
activity in hippocampus of rats (ANOVA, F(8–27) = 15.51; p<0.05;
Fig. 1(A)). Moreover, the activity of citrate synthase increased in
striatum of rats after acute administration of olanzapine in doses
of 3 and 6mg/kg, ﬂuoxetine in dose of 25mg/kg. In addition olan-
zapine in dose of 3mg/kg in combinationwith ﬂuoxetine, 25mg/kg
also increased citrate synthase activity in striatumof rats compared
to saline group (ANOVA, F(8–26) = 12.69; p<0.05; Fig. 1(A)). Acute
treatment with ﬂuoxetine in dose of 12.5mg/kg did not alter cit-
rate synthase activity when administrated alone or in combination
with olanzapine (p>0.05).
The intraperitoneal treatment with olanzapine and ﬂouxetine
alone or in combination in all doses did not alter the activity of
citrate synthase in prefrontal cortex, hippocampus and striatum in
both, chronic treatments (p>0.05; Fig. 1(B) and (C)).
Discussion
In the present study we evaluated the effects of the antipsy-
chotic olanzapine and antidepressant ﬂuoxetine (alone or in
combination) on citrate synthase activity in rat brain. We showed
that acute treatment with olanzapine and ﬂuoxetine (alone) in
some doses increased the citrate synthase activity in rat brain.
Interestingly acute treatment with olanzapine 3mg/kg and ﬂuoxe-
tine 12.5mg/kg in combination increased citrate synthase activity
in prefrontal cortex, hippocampus and striatum (Fig. 1(A)). Chronic
treatment with olanzapine and ﬂuoxetine alone or in combination
did not alter the citrate synthase activity when the rats were killed
2 or 24h (Fig. 1(B) and (C)) after last administration.
Our results indicate that the effects of the olanzapine and
ﬂuoxetine might involve mitochondrial function, but this effect
is treatment regime-related in some rat brain areas. In fact, we
recently showed that acuteandchronic treatmentswitholanzapine
andﬂuoxetine (alone or in combination) alter creatine kinase activ-
ity in some rat brain areas, such as, hippocampus and prefrontal
cortex [1].
The hippocampus is one of several limbic structures that has
been implicated in mood disorders. In addition, the hippocampus
has connections with the prefrontal cortex, region that is more
directly involved in emotion and cognition and thereby contributes
to othermajor symptomsofmooddisorders [9,13,14]. The striatum
is a dopaminergic area involved to memory [11] and mood disor-
ders [22]. Additionally, striatum also has relation to the start, stop
and direction of motor movement [12].
The addition of an atypical antipsychotic drug to an antide-
pressant drug is observed in clinical practice as a strategy to
treat bipolar depression [15,29] as well as, treatment-resistant
depression [10,27,30] and psychotic depression [35]. In a con-
trolled study [25], subjects with treatment-resistant depression
received olanzapine and ﬂuoxetine alone, or a combination of
both; the combination was associated with signiﬁcantly greater
and faster improvement than was either drug alone. Tamayo et al.
[39] studied the effectiveness of olanzapine/ﬂuoxetine combina-
tion treatment in Puerto Rican patients with bipolar depressive
episode and showed improvements resulting from 7 weeks of
acute olanzapine/ﬂuoxetine combination treatment at a starting
once-daily dose of 12/25mg (mean modal dose was 10.8/27.8
and were maintained in responses for additional 12 weeks with
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big. 1. Effects of the acute (A), chronic 2h (animalswere killed 2h after the last inject
f ﬂuoxetine, olanzapine or ﬂuoxetine/olanzapine (i.p.) on the citrate synthase activi
nalysis of variance followed by Tukey’s test when F was signiﬁcant. Values are exp
s. saline according to ANOVA followed by Tukey post hoc test.
lanzapine and ﬂuoxetine in some doses, in addition ﬂuoxetine
as more effective than olanzapine at 10mg monotherapy. One
ther study in patients with mixed depression in bipolar I dis-
rder showed that olanzapine/ﬂuoxetine combination treatment
/25mg (mean modal dose was 7.4/39.3mg/day) demonstrated
hat olanzapine/ﬂuoxetinewas not signiﬁcantly different from that
f olanzapine alone, but showed a trend in favor of a possible supe-
iority of olanzapine/ﬂuoxetine combination [3].
It is well known that citrate synthase plays an important
ole in brain energy metabolism [37]. Our study showed that
cute treatment with ﬂuoxetine and olanzapine alters citrate syn-
hase activity, suggesting that ﬂuoxetine and olanzapine should be
nvolved inmitochondrial function changes. In fact, treatmentwith
uoxetine and olanzapine alters the creatine kinase activity in rat
rain [1] and mitochondrial respiratory chain (I–IV) (unpublished) and chronic 24h (animalswere killed 24h after the last injection; C) administration
refrontal cortex, hippocampus and striatumof rats. Datawere analyzed by one-way
as nmol TNB formed per minute per mg protein (mean± S.E.M.) of 5 rats. *p<0.05
data yet), and both creatine kinase and mitochondrial respira-
tory chain play a central role in energy metabolism. Moreover,
mitochondrial disease results from a malfunction in biochemical
cascade and the damage to the mitochondrial electron transport
chain has been suggested to be an important factor in the patho-
genesis of a range of neuropsychiatric disorders, such as, bipolar
disorder, depression and schizophrenia [33].
In thiswork,we showed increased citrate synthase activity after
acute treatment with olanzapine and ﬂuoxetine in combination
in prefrontal cortex, hippocampus and striatum. However, chronic
treatment did not alter citrate synthase activity. The reason for this
discrepancy this study is unclear but could be related to desensiti-
zation to the effects of repeated olanzapine and ﬂuoxetine or still
for adaptation mechanism. In this manner, the effects of ﬂuoxetine
and olanzapine in this study might be due to the defense mecha-
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ism. Scaini et al. [34] demonstrated that chronic administration of
ntidepressant paroxetine increased citrate synthase and succinate
ehydrogenase activities in prefrontal cortex, hippocampus, stria-
um and cerebral cortex of rats; in contrast chronic administration
f antidepressants nortriptiline andvenlafaxinedidnot alter citrate
ynthase activity in rat brain. We suggest that effects under citrate
ynthase activity may be dependent action mechanism of different
ntidepressants.
In conclusion we suggested an involvement of citrate synthase
ctivity in mood disorders, as well as, olanzapine and ﬂuoxetine
ffects, but these effects were regime-related in some rat brain
reas.
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